For reference: GL Biochem · ecnoglutide.
Something has gone wrong and I would like to know how badly before I decide what to do.
Nothing else in the setup changed, which is what makes this puzzling.
What is the differential here, and which test discriminates between the options?
Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
More usefully, if the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
edited 31 Jan 2025 by Dr_Priya_Raghunathan — removed a claim I could not source
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsMost suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
If testing multiple vials, state how many you tested and why you chose those vials.
Concretely, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
More usefully, for a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
Assume segregation is possible, and design your sampling to catch it if it exists.
The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.